Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
The most recent EPS for Danaher Corp is $2.06, beating expectations of $1.95.
How did Danaher Corp DHR's revenue perform in the last quarter?
Danaher Corp revenue for the last quarter is $2.06
What is the revenue estimate for Danaher Corp?
According to 23 of Wall street analyst, the revenue estimate of Danaher Corp range from $6.47B to $5.94B
What's the earning quality score for Danaher Corp?
Danaher Corp has a earning quality score of B+/56.89221. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Danaher Corp report earnings?
Danaher Corp next earnings report is expected in 2026-07-20
What are Danaher Corp's expected earnings?
Danaher Corp expected earnings is $6.05B, according to wall-street analysts.
Did Danaher Corp beat earnings expectations?
Danaher Corp recent earnings of $5.95B does not beat expectations.